0001144204-16-102048.txt : 20160516 0001144204-16-102048.hdr.sgml : 20160516 20160516062447 ACCESSION NUMBER: 0001144204-16-102048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160516 ITEM INFORMATION: Material Modifications to Rights of Security Holders FILED AS OF DATE: 20160516 DATE AS OF CHANGE: 20160516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA GENETICS INC CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 161650499 BUSINESS ADDRESS: STREET 1: 2345 EASTLAKE AVENUE EAST STREET 2: SUITE 201 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 2345 EASTLAKE AVENUE EAST STREET 2: SUITE 201 CITY: SEATTLE STATE: WA ZIP: 98102 8-K 1 v440049_8k.htm FORM 8-K

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 16, 2016

 

Atossa Genetics Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35610   26-4753208
(State or other jurisdiction of
incorporation) 		  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

2300 Eastlake Ave. East, Suite 200

Seattle, Washington

  

 

98102

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (206) 325-6086

 

Not Applicable
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 3.03 Material Modification to Rights of Security Holders.

 

As of May 16, 2016, Atossa Genetics Inc. (the “Company”) has outstanding warrants to purchase 4,177,050 shares of common stock exercisable at $1.60 per share and 75,000 shares of common stock exercisable at $1.25 per share, all of which were issued in connection with a private financing on various dates in 2011 (the “2011 Warrants”). The 2011 Warrants were scheduled to expire on June 23, 2016. To allow additional time for the 2011 Warrants to be exercised and to potentially generate future cash proceeds to the Company, on May 16, 2016, the Company decided to extend the expiration date of the Warrants to 5 p.m. Eastern Time on May 8, 2018. No action is required by the holders of the 2011 Warrants to effectuate this modification and all provisions of the 2011 Warrants remain in full force and effect. None of the 2011 Warrants are held by officers, directors or affiliates of the Company.


 

 

* * *

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

         
Date: May 16, 2016 Atossa Genetics Inc.  
     
  By:   /s/ Kyle Guse   
    Kyle Guse  
    Chief Financial Officer, General Counsel and Secretary